GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ambrx Biopharma Inc (NAS:AMAM) » Definitions » Gross Margin %

Ambrx Biopharma (Ambrx Biopharma) Gross Margin % : 0.00% (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Ambrx Biopharma Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Ambrx Biopharma's Gross Profit for the three months ended in Jun. 2023 was $1.15 Mil. Ambrx Biopharma's Revenue for the three months ended in Jun. 2023 was $1.15 Mil. Therefore, Ambrx Biopharma's Gross Margin % for the quarter that ended in Jun. 2023 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Ambrx Biopharma's Gross Margin % or its related term are showing as below:


AMAM's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.53
* Ranked among companies with meaningful Gross Margin % only.

Ambrx Biopharma had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Ambrx Biopharma was 0.00% per year.


Ambrx Biopharma Gross Margin % Historical Data

The historical data trend for Ambrx Biopharma's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ambrx Biopharma Gross Margin % Chart

Ambrx Biopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Gross Margin %
- - - -

Ambrx Biopharma Quarterly Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Gross Margin % Get a 7-Day Free Trial - - - - -

Competitive Comparison of Ambrx Biopharma's Gross Margin %

For the Biotechnology subindustry, Ambrx Biopharma's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ambrx Biopharma's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ambrx Biopharma's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Ambrx Biopharma's Gross Margin % falls into.



Ambrx Biopharma Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Ambrx Biopharma's Gross Margin for the fiscal year that ended in Dec. 2022 is calculated as

Gross Margin % (A: Dec. 2022 )=Gross Profit (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=7.4 / 7.402
=(Revenue - Cost of Goods Sold) / Revenue
=(7.402 - 0) / 7.402
=N/A %

Ambrx Biopharma's Gross Margin for the quarter that ended in Jun. 2023 is calculated as


Gross Margin % (Q: Jun. 2023 )=Gross Profit (Q: Jun. 2023 ) / Revenue (Q: Jun. 2023 )
=1.1 / 1.147
=(Revenue - Cost of Goods Sold) / Revenue
=(1.147 - 0) / 1.147
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Ambrx Biopharma  (NAS:AMAM) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Ambrx Biopharma had a gross margin of N/A% for the quarter that ended in Jun. 2023 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Ambrx Biopharma Gross Margin % Related Terms

Thank you for viewing the detailed overview of Ambrx Biopharma's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ambrx Biopharma (Ambrx Biopharma) Business Description

Traded in Other Exchanges
Address
10975 North Torrey Pines Road, La Jolla, CA, USA, 92037
Ambrx Biopharma Inc is a clinical-stage biologics company focused on discovering and developing a novel class of engineered precision biologics (EPBs) using its proprietary expanded genetic code technology platform that allows incorporating synthetic amino acids (SAAs) into proteins within living cells. Its product pipeline includes ARX788, ARX517, ARX305 among others.
Executives
Cormorant Asset Management, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Sonja Nelson officer: Chief Financial Officer C/O MOTUS GI HOLDINGS, INC., 1301 EAST BROWARD BOULEVARD, 3RD FLOOR, FT. LAUDERDALE FL 33301
Daniel J. O'connor director, officer: President and CEO C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Abhishek Trehan 10 percent owner WHITELEY CHAMBERS, DON STREET, ST. HELIER Y9 JE2 4TR
Darwin Global Master Fund, Ltd. 10 percent owner C/O OGIER GLOBAL (CAYMAN) LIMITED, 89 NEXUS WAY, CAMANA BAY, GRAND CAYMAN E9 KY1-9009
Paul V Maier director 3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Janet Loesberg director C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Kate Hermans director C/O AMBRX BIOPHARMA INC., 10975 TORREY PINES ROAD, LA JOLLA CA 92037
Xiaowei Chang director 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Stephen C. Glover director 108 DOCKSIDE CIRCLE, WESTON FL 33327
Andrew Aromando officer: Chief Operating Officer C/O AMBRX BIOPHARMA INC., 10975 NORTH TORREY PINES ROAD, LA JOLLA CA 92037
Cormorant Private Healthcare Fund Iii Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Cormorant Global Healthcare Master Fund, Lp 10 percent owner 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Bihua Chen 10 percent owner C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116